Clearside Biomedi (CLSD) Stock Price, Quote & News

Latest News on CLSD

Apr 1, 2025, 7:05 AM EDT - 24 days ago

Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 8:31 PM EDT - 4 weeks ago

Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript

Mar 27, 2025, 4:05 PM EDT - 4 weeks ago

Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:05 AM EDT - 4 weeks ago

Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Mar 20, 2025, 7:05 AM EDT - 5 weeks ago

Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Mar 12, 2025, 7:05 AM EDT - 6 weeks ago

Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

Mar 6, 2025, 7:05 AM EST - 7 weeks ago

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Feb 20, 2025, 7:05 AM EST - 2 months ago

Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

Feb 10, 2025, 7:05 AM EST - 2 months ago

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

Feb 4, 2025, 7:05 AM EST - 2 months ago

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference

Jan 28, 2025, 7:05 AM EST - 3 months ago

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

Jan 22, 2025, 7:05 AM EST - 3 months ago

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

Dec 19, 2024, 7:05 AM EST - 4 months ago

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

Nov 25, 2024, 7:05 AM EST - 5 months ago

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

Nov 12, 2024, 8:37 PM EST - 5 months ago

Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 9:05 AM EST - 6 months ago

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Nov 6, 2024, 7:05 AM EST - 6 months ago

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Nov 4, 2024, 7:05 AM EST - 6 months ago

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Oct 31, 2024, 7:05 AM EDT - 6 months ago

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Oct 22, 2024, 7:05 AM EDT - 6 months ago

Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

Oct 9, 2024, 6:30 AM EDT - 7 months ago

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Aug 27, 2024, 7:05 AM EDT - 8 months ago

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Aug 8, 2024, 7:05 AM EDT - 9 months ago

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 1, 2024, 7:05 AM EDT - 9 months ago

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

Jul 24, 2024, 11:23 PM EDT - 9 months ago

Clearside Biomedical, Inc. (CLSD) Suprachoroidal Space Drug Delivery (Transcript)

Jul 22, 2024, 12:00 PM EDT - 9 months ago

Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET

Jul 11, 2024, 7:05 AM EDT - 10 months ago

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Jun 27, 2024, 7:05 AM EDT - 10 months ago

Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

Jun 25, 2024, 12:54 PM EDT - 10 months ago

Why Is Clearside Biomedical Stock Gaining Today?

Jun 12, 2024, 7:05 AM EDT - 11 months ago

Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

May 21, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

May 9, 2024, 9:14 PM EDT - 1 year ago

Clearside Biomedical, Inc. (CLSD) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 1 year ago

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 4:15 PM EDT - 1 year ago

Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

Apr 16, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

Apr 2, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mar 18, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Mar 13, 2024, 12:47 AM EDT - 1 year ago

Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 7:05 AM EST - 1 year ago

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

Feb 7, 2024, 8:00 AM EST - 1 year ago

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

Dec 14, 2023, 7:05 AM EST - 1 year ago

Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Nov 13, 2023, 7:18 PM EST - 1 year ago

Clearside Biomedical, Inc. (CLSD) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 4:05 PM EST - 1 year ago

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 8, 2023, 7:05 AM EST - 1 year ago

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference

Nov 7, 2023, 4:20 PM EST - 1 year ago

Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting

Nov 2, 2023, 7:05 AM EDT - 1 year ago

Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

Nov 1, 2023, 7:05 AM EDT - 1 year ago

Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD

Oct 31, 2023, 7:05 AM EDT - 1 year ago

Market Cap	65.57M
Revenue (ttm)	1.66M
Net Income (ttm)	-34.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,069.28%
Debt to Equity Ratio	0.00

Volume	71,300
Avg Vol	205,252
Day's Range	N/A - N/A
Shares Out	77.28M
Stochastic %K	48%
Beta	2.04
Analysts	Strong Sell
Price Target	$5.71